1. Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohort
- Author
-
Verzeroli, Cristina, Giaccherini, Cinzia, Russo, Laura, Bolognini, Silvia, Gamba, Sara, Tartari, Carmen J., Schieppati, Francesca, Ticozzi, Chiara, Vignoli, Alfonso, Masci, Giovanna, Sarmiento, Roberta, Spinelli, Daniele, Malighetti, Paolo, Tondini, Carlo, Petrelli, Fausto, Giuliani, Francesco, D’Alessio, Andrea, Gasparini, Giampietro, Minelli, Mauro, De Braud, Filippo, Santoro, Armando, Labianca, Roberto, Marchetti, Marina, Falanga, Anna, Marina, Marchetti, Silvia, Bolognini, Sara, Gamba, Cinzia, Giaccherini, Laura, Russo, Francesca, Schieppati, Julia, Tartari Carmen, Chiara, Ticozzi, Cristina, Verzeroli, Alfonso, Vignoli, Armando, Santoro, Giovanna, Masci, Filippo, De Braud, Antonia, Martinetti, Carlo, Tondini, Roberto, Labianca, Giampietro, Gasparini, Roberta, Sarmiento, Elisabetta, Gennaro, Mauro, Minelli, Sandro, Barni, Fausto, Petrelli, Mara, Ghilardi, Andrea, D’Alessio, Sara, Cecchini, Francesco, Giuliani, Paolo, Malighetti, Chiara, Morlotti, Daniele, Spinelli, and Falanga, Anna
- Abstract
Risk assessment models (RAMs) are relevant approaches to identify cancer outpatients at high risk of venous thromboembolism (VTE). Among the proposed RAMs, the Khorana (KRS) and the new-Vienna CATS risk scores have been externally validated in ambulatory patients with cancer.
- Published
- 2023
- Full Text
- View/download PDF